p97/VCP inhibition causes excessive MRE11-dependent DNA end resection promoting cell killing after ionizing radiation.

CB-5083 DNA damage DNA double-strand break repair IR MRE11 bladder cancer homologous recombination ionizing radiation p97 single-strand annealing

Journal

Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691

Informations de publication

Date de publication:
25 05 2021
Historique:
received: 05 02 2020
revised: 16 03 2021
accepted: 28 04 2021
entrez: 26 5 2021
pubmed: 27 5 2021
medline: 11 2 2022
Statut: ppublish

Résumé

The ATPase p97 is a central component of the ubiquitin-proteasome degradation system. p97 uses its ATPase activity and co-factors to extract ubiquitinated substrates from different cellular locations, including DNA lesions, thereby regulating DNA repair pathway choice. Here, we find that p97 physically and functionally interacts with the MRE11-RAD50-NBS1 (MRN) complex on chromatin and that inactivation of p97 blocks the disassembly of the MRN complex from the sites of DNA damage upon ionizing radiation (IR). The inhibition of p97 function results in excessive 5'-DNA end resection mediated by MRE11 that leads to defective DNA repair and radiosensitivity. In addition, p97 inhibition by the specific small-molecule inhibitor CB-5083 increases tumor cell killing following IR both in vitro and in vivo. Mechanistically, this is mediated via increased MRE11 nuclease accumulation. This suggests that p97 inhibitors might be exploited to improve outcomes for radiotherapy patients.

Identifiants

pubmed: 34038735
pii: S2211-1247(21)00495-2
doi: 10.1016/j.celrep.2021.109153
pmc: PMC8170441
pii:
doi:

Substances chimiques

Nuclear Proteins 0
DNA 9007-49-2
MRE11 Homologue Protein EC 3.1.-
Adenosine Triphosphatases EC 3.6.1.-
p97 ATPase EC 3.6.1.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

109153

Subventions

Organisme : Medical Research Council
ID : MC_PC_12001/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC 12001/1
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C5255/A23755
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00001/1
Pays : United Kingdom

Informations de copyright

Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests The authors declare no competing interests.

Références

Nat Struct Mol Biol. 2016 Aug;23(8):714-21
pubmed: 27348077
Nat Struct Mol Biol. 2011 Nov 27;18(12):1345-50
pubmed: 22120668
Nature. 2016 Jul 20;535(7612):382-7
pubmed: 27443740
Trends Biochem Sci. 2011 Oct;36(10):515-23
pubmed: 21741246
Nat Cell Biol. 2012 Feb 02;14(2):117-23
pubmed: 22298039
Cell. 2003 Oct 31;115(3):355-67
pubmed: 14636562
J Cell Sci. 2014 Sep 15;127(Pt 18):3877-83
pubmed: 25146396
Mol Cell Biol. 2000 Nov;20(22):8602-12
pubmed: 11046155
Nucleic Acids Res. 2014 Feb;42(4):2380-90
pubmed: 24319145
Nat Rev Mol Cell Biol. 2011 Feb;12(2):90-103
pubmed: 21252998
Mol Cancer Ther. 2018 Feb;17(2):381-392
pubmed: 28839000
Trends Cell Biol. 2012 Sep;22(9):483-91
pubmed: 22818974
Int J Hyperthermia. 2004 Mar;20(2):157-62
pubmed: 15195510
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Cell Cycle. 2016;15(6):787-98
pubmed: 26766492
Cell. 2019 Jan 24;176(3):505-519.e22
pubmed: 30612738
Nat Cell Biol. 2011 Aug 07;13(9):1116-23
pubmed: 21822278
Mol Cell. 2016 Nov 17;64(4):704-719
pubmed: 27871366
Nature. 2009 Mar 26;458(7237):453-60
pubmed: 19325625
Cancers (Basel). 2019 Jan 09;11(1):
pubmed: 30634515
Mol Cell. 2019 Aug 8;75(3):605-619.e6
pubmed: 31255466
Mol Cell. 2018 Aug 2;71(3):419-427
pubmed: 30057197
Nat Cell Biol. 2011 Oct 23;13(11):1376-82
pubmed: 22020440
Mol Cell. 2021 Mar 18;81(6):1292-1308.e11
pubmed: 33567269
Ann Surg Oncol. 2004 Jul;11(7):697-704
pubmed: 15231524
Nat Struct Mol Biol. 2010 Nov;17(11):1305-11
pubmed: 20935632
Nature. 2018 Aug;560(7716):122-127
pubmed: 30046110
Nucleic Acids Res. 2016 Jul 8;44(12):5743-57
pubmed: 27131361
PLoS One. 2013 Sep 17;8(9):e74415
pubmed: 24069311
Mol Cell. 2019 Sep 19;75(6):1299-1314.e6
pubmed: 31353207
Mol Cell. 2013 Apr 11;50(1):116-22
pubmed: 23582259
Nucleic Acids Res. 2019 Jul 2;47(W1):W556-W560
pubmed: 31114875
PLoS Biol. 2010 Jun 29;8(6):e1000412
pubmed: 20613859
Nature. 1996 Aug 8;382(6591):551-5
pubmed: 8700231
Clin Cancer Res. 2004 May 1;10(9):3007-12
pubmed: 15131036
Mol Cancer Ther. 2017 Nov;16(11):2375-2386
pubmed: 28878026
Nature. 2018 Nov;563(7732):522-526
pubmed: 30464262
Mol Cell. 2019 Jul 11;75(1):145-153.e5
pubmed: 31153714
Front Genet. 2016 May 03;7:73
pubmed: 27200082
Trends Genet. 2016 Sep;32(9):566-575
pubmed: 27450436
Cell Rep. 2021 Feb 16;34(7):108713
pubmed: 33596428
EMBO J. 1999 Dec 1;18(23):6619-29
pubmed: 10581236
Cell Death Dis. 2021 Feb 8;12(2):165
pubmed: 33558481
BMC Biol. 2014 Nov 11;12:94
pubmed: 25385277
Trends Cell Biol. 2016 Jan;26(1):52-64
pubmed: 26437586
Nature. 2007 Dec 20;450(7173):1258-62
pubmed: 18097415
Nucleic Acids Res. 2019 Jan 8;47(D1):D442-D450
pubmed: 30395289
Cell Mol Life Sci. 2008 Aug;65(15):2360-71
pubmed: 18438607
Science. 2014 Oct 24;346(6208):477-81
pubmed: 25342805
J Med Chem. 2015 Dec 24;58(24):9480-97
pubmed: 26565666
Mol Cell Proteomics. 2012 Feb;11(2):M111.013904
pubmed: 21997733
Cell. 2008 Oct 3;135(1):85-96
pubmed: 18854157
EMBO J. 2019 Oct 4;38(21):e102361
pubmed: 31613024
Nucleic Acids Res. 2015 Sep 30;43(17):8352-67
pubmed: 26240375
Mol Cell. 2016 Oct 6;64(1):189-198
pubmed: 27716483
Cancer Res. 2017 Jun 1;77(11):3027-3039
pubmed: 28363998
Philos Trans R Soc Lond B Biol Sci. 2017 Oct 5;372(1731):
pubmed: 28847819
Clin Cancer Res. 2004 Aug 15;10(16):5558-65
pubmed: 15328197
Cell. 2011 May 13;145(4):529-42
pubmed: 21565612
J Cell Biol. 2003 Jul 7;162(1):71-84
pubmed: 12847084
Nat Commun. 2019 Jul 4;10(1):2954
pubmed: 31273204
Mol Cell. 2018 Jan 18;69(2):182-194
pubmed: 29153394
Cell Cycle. 2010 Sep 15;9(18):3798-806
pubmed: 20890109
Mol Cell. 2017 Feb 16;65(4):671-684.e5
pubmed: 28132842
Biochem Soc Trans. 2008 Feb;36(Pt 1):62-7
pubmed: 18208387
Eur Urol. 2014 Sep;66(3):597-8
pubmed: 25306182
Cancer Cell. 2015 Nov 9;28(5):653-665
pubmed: 26555175
Eur Urol. 2017 Mar;71(3):462-475
pubmed: 27375033
Mol Cell. 2014 Jan 9;53(1):7-18
pubmed: 24316220
Clin Cancer Res. 2004 Jan 15;10(2):651-7
pubmed: 14760088
Nat Rev Cancer. 2004 May;4(5):349-60
pubmed: 15122206
Cell. 2017 May 18;169(5):792-806
pubmed: 28525752

Auteurs

Susan Kilgas (S)

MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford OX3 7DQ, UK.

Abhay Narayan Singh (AN)

MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford OX3 7DQ, UK.

Salome Paillas (S)

MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford OX3 7DQ, UK.

Chee-Kin Then (CK)

MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford OX3 7DQ, UK.

Ignacio Torrecilla (I)

MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford OX3 7DQ, UK.

Judith Nicholson (J)

MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford OX3 7DQ, UK.

Lisa Browning (L)

Department of Cellular Pathology, Oxford University Hospitals, NHS Foundation Trust, Oxford OX3 9DU, UK.

Iolanda Vendrell (I)

MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford OX3 7DQ, UK; TDI Mass Spectrometry Laboratory, Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7FZ, UK.

Rebecca Konietzny (R)

TDI Mass Spectrometry Laboratory, Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7FZ, UK.

Benedikt M Kessler (BM)

TDI Mass Spectrometry Laboratory, Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7FZ, UK.

Anne E Kiltie (AE)

MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford OX3 7DQ, UK. Electronic address: anne.kiltie@oncology.ox.ac.uk.

Kristijan Ramadan (K)

MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford OX3 7DQ, UK. Electronic address: kristijan.ramadan@oncology.ox.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH